ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Total Equity history
Currency unavailable · from the balance sheet
No Total Equity data reported for this period type.
Total Equity vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $511.73M USD | +197.9% | — | 87.7% | |
| Mar 2026 | $394.88M USD | +12.8% | +24.0% | 89.1% | |
| Mar 2026 | $234.1M USD | — | — | 80.1% | |
| Mar 2026 | $191.36M USD | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $183.33M USD | +87.9% | +223.2% | 98.0% | |
| Mar 2026 | $76.7M USD | -28.3% | -27.4% | 26.0% | |
| Mar 2026 | $49.4M USD | +143.8% | +41.3% | 42.9% | |
| Mar 2026 | €37.64M EUR | -55.9% | -9.5% | 38.0% | |
| Mar 2026 | -$58.13M USD | -275.6% | — | 23.8% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -2.7% | +8.3% | 78.0% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.